Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Falls 9.6% on Analyst Downgrade

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) were down 9.6% on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $10.00 to $7.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Recursion Pharmaceuticals traded as low as $2.89 and last traded at $2.8750. 12,297,236 shares traded hands during trading, a decline of 37% from the average daily volume of 19,608,584 shares. The stock had previously closed at $3.18.

Several other research firms have also issued reports on RXRX. Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Monday, October 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, October 15th. Morgan Stanley set a $5.90 price target on shares of Recursion Pharmaceuticals in a research report on Friday, October 16th. Finally, Wall Street Zen raised shares of Recursion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $7.58.

View Our Latest Report on Recursion Pharmaceuticals

Insider Activity

In other news, CEO Najat Khan sold 22,408 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total value of $78,876.16. Following the transaction, the chief executive officer directly owned 2,072,890 shares in the company, valued at $7,296,572.80. The trade was a 1.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 50,000 shares of the company’s stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $4.84, for a total value of $242,000.00. Following the completion of the transaction, the director directly owned 6,108,287 shares of the company’s stock, valued at approximately $29,564,109.08. This trade represents a 0.81% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 167,408 shares of company stock worth $701,276 over the last ninety days. Corporate insiders own 6.65% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC bought a new stake in Recursion Pharmaceuticals in the 1st quarter valued at $7,370,000. Bank of New York Mellon Corp lifted its stake in Recursion Pharmaceuticals by 29.3% in the 1st quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company’s stock worth $4,490,000 after purchasing an additional 331,048 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Recursion Pharmaceuticals by 18.2% during the 1st quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock valued at $7,665,000 after purchasing an additional 384,486 shares during the last quarter. First Trust Advisors LP boosted its holdings in shares of Recursion Pharmaceuticals by 15.2% during the 1st quarter. First Trust Advisors LP now owns 2,610,726 shares of the company’s stock valued at $8,015,000 after purchasing an additional 344,035 shares during the last quarter. Finally, California State Teachers Retirement System grew its position in shares of Recursion Pharmaceuticals by 64.0% during the first quarter. California State Teachers Retirement System now owns 574,637 shares of the company’s stock valued at $1,764,000 after purchasing an additional 224,332 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Price Performance

The stock has a market cap of $1.69 billion, a PE ratio of -3.02 and a beta of 1.15. The stock has a 50-day moving average price of $3.75 and a two-hundred day moving average price of $3.47.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last issued its earnings results on Monday, November 2nd. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.22). The firm had revenue of $18.55 million for the quarter, compared to analysts’ expectations of $14.81 million. Recursion Pharmaceuticals had a negative return on equity of 47.85% and a negative net margin of 697.15%. During the same period in the previous year, the firm posted ($0.36) earnings per share. Equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -0.89 earnings per share for the current year.

About Recursion Pharmaceuticals

(Get Free Report)

Recursion Pharmaceuticals, Inc. is a biotechnology company that uses automation, large-scale biological and chemical data, and machine learning to discover and develop medicines. Its platform, known as Recursion OS, is designed to identify relationships between biological processes and potential treatments. The company develops drug candidates for areas including rare diseases and oncology, and it also works with pharmaceutical partners on drug discovery and development. Its research combines laboratory experiments with computational analysis to evaluate potential therapeutic targets and compounds.

Featured Stories

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.